| Grant ID | DP240248 |
| Awarded On | May 15, 2024 |
| Title | AHA-1031 engages two strong activating receptors (NKG2D/MICA and CD16/engineered Fc) in the tumor microenviroment for the treatment of advanced NSCLC |
| Program | Product Development Research |
| Award Mechanism | Seed Awards for Product Development Research |
| Institution/Organization | Aakha Biologics |
| Principal Investigator/Program Director | Hemanta Baruah |
| Cancer Sites | Lung and Bronchus |
| Contracted Amount |
$2,549,580* *Pending contract negotiation |
| Lay Summary |
Advanced metastatic lung cancer is the deadliest form of cancer but is difficult to treat because many tumors lack immune cells that are critical for fighting the cancer. Despite the discovery and advancement of newer therapies that target specific cancers, the patient's overall 5-year survival rate is only 9%. Based in Frisco TX, Aakha Biologics is developing a novel antibody drug that has the potential to both attract these immune cells to the tumor and activate them to kill the tumor. This antibody binds to an a newly validated cancer target on the surface of tumors and then specifically recruits killer cells to destroy the tumor. This project aims to complete studies that will further d... |